Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an injectable solution for intravenous use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor used to manage conditions driven by excess gastric acid secretion.

Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. Peptic ulcer disease: supports ulcer healing by maintaining a higher gastric pH. Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors.

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limited. - Nausea: transient and often resolves. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile infection: severe colitis associated with altered gut flora. - Hypomagnesemia: low serum magnesium levels, may cause muscle cramps. - Elevated liver enzymes: indication of hepatic stress. - Stevens‑Johnson syndrome: rare severe skin reaction. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications.

Renal impairment: adjust monitoring as the drug is primarily excreted renally. Hepatic impairment: use with caution in patients with severe liver disease. Elderly patients: monitor for electrolyte disturbances and dehydration. Concomitant acid‑dependent drugs: assess efficacy of medications that require an acidic environment. Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole may alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing thrombotic risk. - Atazanavir: decreased absorption, compromising antiviral efficacy. - High‑dose methotrexate: increased toxicity due to reduced renal clearance. - Warfarin: potential alteration of INR, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations, risk of toxicity. - Diazepam: elevated levels may enhance sedation. - Phenytoin: decreased levels, possibly reducing seizure control.